This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights GenFleet Therapeutics’ HKEX IPO, Sciwind’s IPO filing for enoglutide, Biocytogen’s STAR Market approval, Hengrui’s HER2 ADC licensing deal with Glenmark, and AusperBio’s US$63M Series B2 financing. Clinical updates include AbbVie’s FL filing for Epcoritamab, Ascletis’ THRβ agonist ASC47 weight loss results, Zelgen’s trispecific antibody Phase III trial for SCLC, Keymed’s BCMA/CD3 bispecific Phase III trial in MM, and Akeso’s HER3-targeting ADC clinical approval.
